GLP-1 Receptor Agonists in Alzheimer's Disease and Beyond

Mechanism of Action and Receptor Location

GLP-1 receptors are found in the brain, including the hypothalamus and brainstem nuclei, providing a biological basis for potential central nervous system effects 1

GLP-1 receptor agonists have established benefits for type 2 diabetes management and obesity treatment with significant weight reduction effects 1
These medications demonstrate cardiovascular benefits, including a 13% reduction in primary composite outcome of cardiovascular death, non-fatal myocardial infarction, or stroke in the LEADER trial (liraglutide) 1
A 26% reduction in cardiovascular events was observed in the SUSTAIN-6 trial (semaglutide) 1

Common side effects of GLP-1 receptor agonists include gastrointestinal symptoms (nausea, vomiting, diarrhea), which are dose-dependent and generally more common with short-acting than long-acting formulations 2
Contraindications include personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia type 2 1
History of pancreatitis is a precaution for GLP-1 receptor agonist use 1, 2

For patients with both type 2 diabetes and Alzheimer's disease, GLP-1 receptor agonists may be considered for diabetes management, with potential (though unproven) additional benefits for cognitive function 3
Starting at a low dose and titrating slowly minimizes gastrointestinal side effects when initiating GLP-1 receptor agonists 1
Patients should be monitored for common adverse effects, particularly gastrointestinal symptoms, which can be mitigated by reducing meal size 1, 2